Revive Expands Phase 3 COVID-19 Study To Asia Pacific Region, Canada

Revive Therapeutics (CSE: RVV) announced this morning that it is expanding its phase 3 clinical trials following the approval granted by the US Food and Drug Administration. The company is expanding its plans to include both Asia-Pacific Countries (APAC) as well as Canada.

The phase 3 trials, which consist of the company studying the use of Bucillamine in the treatment of mild-moderate COVID-19 and other infectious diseases, are currently expected to open for patient enrollment and dosing next month in September. Revive and its clinical trial partners are currently evaluating potential clinical sites, which includes the previously announced states of California, Florida, Arizona and Texas as well as in the additional US states and now Canada and the APAC region.

The announcement of the expansion of the clinical trial regions follows the announcement last week that the company has signed a memorandum of understanding with Attwill Medical Solutions Sterilflow, LP, the same firm utilized by Vaxart Inc (NASDAQ: VXRT) for its clinical stage oral COVID vaccine, as a resource for clinical packaging and distribution of the phase 3 clinical trial. Further vendor agreements are in the process of being finalized currently.

“With the approval from the FDA to conduct the Phase 3 clinical trial in COVID-19 and our progress that we have made to date, we are now establishing plans to complement and support our initiatives in the U.S. to include clinical sites in APAC and Canada.”

Michael Frank, CEO of Revive Therapeutics

The scientific rationale for the use of Bucillamine in the treatment of COVID-19, as well as the details of the phase 3 confirmatory clinical study, can be found here.

Revive Therapeutics last traded at $0.28 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Gold Drilling Scaled to 60,000 Meters: How Big Can This Get? | Roger Rosmus – Goliath Resources

Baselode Energy To Acquire Forum Energy: The Merger Of Equals Deal

TriStar Gold: The Revised Castelo de Sonhos Prefeasibility Study

Recommended

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Related News

Revive Submits for IRB Approval; Expects to Enroll Patients in September

This morning Revive Therapeutics (CSE: RVV, USA: RVVTF) announced they have submitted a clinical trial...

Wednesday, August 26, 2020, 10:07:43 AM

Revive Expects To Complete Phase 3 Interim Analysis In December On Bucillamine In Treatment of COVID-19

Revive Therapeutics (CSE: RVV) provided an update on the status of its ongoing phase three...

Monday, October 26, 2020, 10:54:38 AM

Revive Therapeutics Sees Research Partnership On Psilocybin Expanded

Revive Therapeutics (CSE: RVV) has expanded its sponsored research partnership agreement with that of the...

Friday, June 12, 2020, 08:46:44 AM

Revive Therapeutics To Conduct Phase 1 Clinical Trials For Psilocybin

Revive Therapeutics (CSE: RVV) is driving forward with its psilocybin studies. The company announced this...

Wednesday, September 2, 2020, 08:43:51 AM

Revive Therapeutics Provides Market Update On Cannabinoid Related Research

Revive Therapeutics (CSE: RVV) this morning provided an update in connection with its ongoing cannabinoid...

Thursday, February 11, 2021, 08:01:25 AM